{"pmid":32488957,"title":"Procedures for Flow Cytometry-Based Sorting of Unfixed Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infected Cells and Other Infectious Agents.","text":["Procedures for Flow Cytometry-Based Sorting of Unfixed Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infected Cells and Other Infectious Agents.","In response to the recent COVID-19 pandemic, many laboratories are involved in research supporting SARS-CoV-2 vaccine development and clinical trials. Flow cytometry laboratories will be responsible for a large part of this effort by sorting unfixed antigen-specific lymphocytes. Therefore, it is critical and timely that we have an understanding of risk assessment and established procedures of infectious cell sorting. Here we present procedures covering the biosafety aspects of sorting unfixed SARS-CoV-2-infected cells and other infectious agents of similar risk level. These procedures follow the ISAC Biosafety Committee guidelines and were recently approved by the National Institutes of Health Institutional Biosafety Committee for sorting SARS-CoV-2-infected cells. (c) 2020 International Society for Advancement of Cytometry.","Cytometry A","Reifel, Kristen M","Swan, Brandon K","Jellison, Evan R","Ambrozak, David","Baijer, Jan","Nguyen, Richard","Monard, Simon","Lyon, Geoffrey","Fontes, Benjamin","Perfetto, Stephen P","32488957"],"abstract":["In response to the recent COVID-19 pandemic, many laboratories are involved in research supporting SARS-CoV-2 vaccine development and clinical trials. Flow cytometry laboratories will be responsible for a large part of this effort by sorting unfixed antigen-specific lymphocytes. Therefore, it is critical and timely that we have an understanding of risk assessment and established procedures of infectious cell sorting. Here we present procedures covering the biosafety aspects of sorting unfixed SARS-CoV-2-infected cells and other infectious agents of similar risk level. These procedures follow the ISAC Biosafety Committee guidelines and were recently approved by the National Institutes of Health Institutional Biosafety Committee for sorting SARS-CoV-2-infected cells. (c) 2020 International Society for Advancement of Cytometry."],"journal":"Cytometry A","authors":["Reifel, Kristen M","Swan, Brandon K","Jellison, Evan R","Ambrozak, David","Baijer, Jan","Nguyen, Richard","Monard, Simon","Lyon, Geoffrey","Fontes, Benjamin","Perfetto, Stephen P"],"date":"2020-06-04T11:00:00Z","year":2020,"_id":"32488957","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1002/cyto.a.24040","keywords":["covid-19","isac biosafety committee","sars-cov-2 cell sorting procedure","biosafety and cell sorting","coronavirus","infectious cell sorting"],"topics":["Prevention"],"weight":1,"_version_":1668892169400745984,"score":9.490897,"similar":[{"pmid":32275124,"title":"Handling and Processing of Blood Specimens from Patients with COVID-19 for Safe Studies on Cell Phenotype and Cytokine Storm.","text":["Handling and Processing of Blood Specimens from Patients with COVID-19 for Safe Studies on Cell Phenotype and Cytokine Storm.","The pandemic caused by severe acute respiratory syndrome coronavirus 2 heavily involves all those working in a laboratory. Samples from known infected patients or donors who are considered healthy can arrive, and a colleague might be asymptomatic but able to transmit the virus. Working in a clinical laboratory is posing several safety challenges. Few years ago, International Society for Advancement of Cytometry published guidelines to safely analyze and sort human samples that were revised in these days. We describe the procedures that we have been following since the first patient appeared in Italy, which have only slightly modified our standard one, being all human samples associated with risks. (c) 2020 International Society for Advancement of Cytometry.","Cytometry A","Cossarizza, Andrea","Gibellini, Lara","De Biasi, Sara","Lo Tartaro, Domenico","Mattioli, Marco","Paolini, Annamaria","Fidanza, Lucia","Bellinazzi, Caterina","Borella, Rebecca","Castaniere, Ivana","Meschiari, Marianna","Sita, Marco","Manco, Gianrocco","Clini, Enrico","Gelmini, Roberta","Girardis, Massimo","Guaraldi, Giovanni","Mussini, Cristina","32275124"],"abstract":["The pandemic caused by severe acute respiratory syndrome coronavirus 2 heavily involves all those working in a laboratory. Samples from known infected patients or donors who are considered healthy can arrive, and a colleague might be asymptomatic but able to transmit the virus. Working in a clinical laboratory is posing several safety challenges. Few years ago, International Society for Advancement of Cytometry published guidelines to safely analyze and sort human samples that were revised in these days. We describe the procedures that we have been following since the first patient appeared in Italy, which have only slightly modified our standard one, being all human samples associated with risks. (c) 2020 International Society for Advancement of Cytometry."],"journal":"Cytometry A","authors":["Cossarizza, Andrea","Gibellini, Lara","De Biasi, Sara","Lo Tartaro, Domenico","Mattioli, Marco","Paolini, Annamaria","Fidanza, Lucia","Bellinazzi, Caterina","Borella, Rebecca","Castaniere, Ivana","Meschiari, Marianna","Sita, Marco","Manco, Gianrocco","Clini, Enrico","Gelmini, Roberta","Girardis, Massimo","Guaraldi, Giovanni","Mussini, Cristina"],"date":"2020-04-11T11:00:00Z","year":2020,"_id":"32275124","source":"PubMed","week":"202015|Apr 06 - Apr 12","doi":"10.1002/cyto.a.24009","keywords":["covid-19","sars-cov-2","biosafety","coronavirus","cytokines","cytometry"],"locations":["Italy"],"countries":["Italy"],"countries_codes":["ITA|Italy"],"topics":["Prevention"],"weight":1,"_version_":1666138491732361216,"score":319.78033},{"pmid":32268455,"title":"[Work flow of clinical microbiology laboratory under the outbreak of the novel coronavirus disease 2019].","text":["[Work flow of clinical microbiology laboratory under the outbreak of the novel coronavirus disease 2019].","The burn microbiology laboratory of the author's unit is a second-level biosafety laboratory, which is mainly responsible for handling clinical microbial samples from our department and other departments in the hospital. Since the outbreak of the coronavirus disease 2019, in order to ensure the normal development of daily work and the safety of medical staff, the microbiology laboratory has actively adjusted the daily work flow. The specific work flow is summarized as follows to provide reference for the safety protection of peer in clinical microbiology laboratory.","Zhonghua Shao Shang Za Zhi","Gong, Y L","Shi, Y L","Luo, X Q","Zhang, C","Liu, M X","Chen, Y","Peng, Y Z","32268455"],"abstract":["The burn microbiology laboratory of the author's unit is a second-level biosafety laboratory, which is mainly responsible for handling clinical microbial samples from our department and other departments in the hospital. Since the outbreak of the coronavirus disease 2019, in order to ensure the normal development of daily work and the safety of medical staff, the microbiology laboratory has actively adjusted the daily work flow. The specific work flow is summarized as follows to provide reference for the safety protection of peer in clinical microbiology laboratory."],"journal":"Zhonghua Shao Shang Za Zhi","authors":["Gong, Y L","Shi, Y L","Luo, X Q","Zhang, C","Liu, M X","Chen, Y","Peng, Y Z"],"date":"2020-04-09T11:00:00Z","year":2020,"_id":"32268455","source":"PubMed","week":"202015|Apr 06 - Apr 12","doi":"10.3760/cma.j.cn501120-20200303-00117","keywords":["biosafety protection","burns","clinical microbiology laboratory","severe acute respiratory syndrome coronavirus 2","workflow"],"topics":["Prevention"],"weight":1,"_version_":1666138491921104896,"score":197.05406},{"pmid":32396137,"title":"Biosafety measures for preventing infection from COVID-19 in clinical laboratories: IFCC Taskforce Recommendations.","text":["Biosafety measures for preventing infection from COVID-19 in clinical laboratories: IFCC Taskforce Recommendations.","Coronavirus disease 2019 (COVID-19) is the third coronavirus outbreak that has emerged in the past 20 years, after severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS). One important aspect, highlighted by many global health organizations, is that this novel coronavirus outbreak may be especially hazardous to healthcare personnel, including laboratory professionals. Therefore, the aim of this document, prepared by the COVID-19 taskforce of the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC), is to provide a set of recommendations, adapted from official documents of international and national health agencies, on biosafety measures for routine clinical chemistry laboratories that operate at biosafety levels 1 (BSL-1; work with agents posing minimal threat to laboratory workers) and 2 (BSL-2; work with agents associated with human disease which pose moderate hazard). We believe that the interim measures proposed in this document for best practice will help minimazing the risk of developing COVID-19 while working in clinical laboratories.","Clin Chem Lab Med","Lippi, Giuseppe","Adeli, Khosrow","Ferrari, Maurizio","Horvath, Andrea R","Koch, David","Sethi, Sunil","Wang, Cheng-Bin","32396137"],"abstract":["Coronavirus disease 2019 (COVID-19) is the third coronavirus outbreak that has emerged in the past 20 years, after severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS). One important aspect, highlighted by many global health organizations, is that this novel coronavirus outbreak may be especially hazardous to healthcare personnel, including laboratory professionals. Therefore, the aim of this document, prepared by the COVID-19 taskforce of the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC), is to provide a set of recommendations, adapted from official documents of international and national health agencies, on biosafety measures for routine clinical chemistry laboratories that operate at biosafety levels 1 (BSL-1; work with agents posing minimal threat to laboratory workers) and 2 (BSL-2; work with agents associated with human disease which pose moderate hazard). We believe that the interim measures proposed in this document for best practice will help minimazing the risk of developing COVID-19 while working in clinical laboratories."],"journal":"Clin Chem Lab Med","authors":["Lippi, Giuseppe","Adeli, Khosrow","Ferrari, Maurizio","Horvath, Andrea R","Koch, David","Sethi, Sunil","Wang, Cheng-Bin"],"date":"2020-05-13T11:00:00Z","year":2020,"_id":"32396137","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1515/cclm-2020-0633","keywords":["covid-19","sars-cov-2","biosafety","coronavirus disease 2019","laboratory"],"topics":["Prevention"],"weight":1,"_version_":1666627827822231552,"score":188.38},{"pmid":32391660,"title":"[Principles and suggestions on biosafety protection of biological specimen preservation during prevalence of COVID-19].","text":["[Principles and suggestions on biosafety protection of biological specimen preservation during prevalence of COVID-19].","Coronavirus disease 2019 (COVID-19) is a grade B infectious disease caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). In pace with the spreading of the disease, biosafety risk of the biological specimen preservation in biobanks has been significantly increased and biosafety protection during biological specimen preservation become increasingly important. According to the related national rules and the corresponding guidelines of Chinese Medical Association, this paper introduced the etiology about SARS-CoV-2, epidemiology about COVID-19, and the biosafety protection principles of individuals and biological specimen storage places in the process of personal protection, protection of collection, transport, handling, preservation, detection, post-detection disposal and emergencies of biological specimen. Emphasized to carry out a strict biosafety-risk assessment on biological specimen basing on virus load information, infectivity, and sample type (possible contact transmission, aerosol transmission, and fecal oral transmission).","Zhejiang Da Xue Xue Bao Yi Xue Ban","Zhang, Xiaoyan","Sun, Wei","Shang, Shiqiang","Mao, Jianhua","Fu, Junfen","Shu, Qiang","Jiang, Kewen","32391660"],"abstract":["Coronavirus disease 2019 (COVID-19) is a grade B infectious disease caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). In pace with the spreading of the disease, biosafety risk of the biological specimen preservation in biobanks has been significantly increased and biosafety protection during biological specimen preservation become increasingly important. According to the related national rules and the corresponding guidelines of Chinese Medical Association, this paper introduced the etiology about SARS-CoV-2, epidemiology about COVID-19, and the biosafety protection principles of individuals and biological specimen storage places in the process of personal protection, protection of collection, transport, handling, preservation, detection, post-detection disposal and emergencies of biological specimen. Emphasized to carry out a strict biosafety-risk assessment on biological specimen basing on virus load information, infectivity, and sample type (possible contact transmission, aerosol transmission, and fecal oral transmission)."],"journal":"Zhejiang Da Xue Xue Bao Yi Xue Ban","authors":["Zhang, Xiaoyan","Sun, Wei","Shang, Shiqiang","Mao, Jianhua","Fu, Junfen","Shu, Qiang","Jiang, Kewen"],"date":"2020-05-12T11:00:00Z","year":2020,"_id":"32391660","source":"PubMed","week":"202020|May 11 - May 17","topics":["Prevention"],"weight":1,"_version_":1666528579965419520,"score":174.86478},{"pmid":32275081,"title":"Evaluate severe acute respiratory syndrome coronavirus 2 infectivity by pseudoviral particles.","text":["Evaluate severe acute respiratory syndrome coronavirus 2 infectivity by pseudoviral particles.","Since the outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in humans in late 2019, it has rapidly spread worldwide. To identify the biological characteristics of SARS-CoV-2 in a normal laboratory environment (biosafety level 2 [BSL-2]), a lentiviral-based nucleocapsid was used to carry the spike protein of SARS-CoV-2 onto the surface of pseudoviral particles as a surrogate model to evaluate the infective characterization of SARS-CoV-2. This study indicated that SARS-CoV-2 has extensive tissue tropism for humans and may infect monkeys and tree shrews but not rodents. More importantly, the use of pseudoviral particles in this study allows rapid assessment of neutralizing antibodies in serum in a BSL-2 laboratory. This study will provide a quick and easy tool for evaluating neutralizing antibodies in the serum of recovering patients and assessing the potency of candidate vaccines.","J Med Virol","Pu, Tao","Ding, Chen","Li, Yadong","Liu, Xiaojuan","Li, Haiwei","Duan, Jinmei","Zhang, Heng","Bi, Yanwei","Cun, Wei","32275081"],"abstract":["Since the outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in humans in late 2019, it has rapidly spread worldwide. To identify the biological characteristics of SARS-CoV-2 in a normal laboratory environment (biosafety level 2 [BSL-2]), a lentiviral-based nucleocapsid was used to carry the spike protein of SARS-CoV-2 onto the surface of pseudoviral particles as a surrogate model to evaluate the infective characterization of SARS-CoV-2. This study indicated that SARS-CoV-2 has extensive tissue tropism for humans and may infect monkeys and tree shrews but not rodents. More importantly, the use of pseudoviral particles in this study allows rapid assessment of neutralizing antibodies in serum in a BSL-2 laboratory. This study will provide a quick and easy tool for evaluating neutralizing antibodies in the serum of recovering patients and assessing the potency of candidate vaccines."],"journal":"J Med Virol","authors":["Pu, Tao","Ding, Chen","Li, Yadong","Liu, Xiaojuan","Li, Haiwei","Duan, Jinmei","Zhang, Heng","Bi, Yanwei","Cun, Wei"],"date":"2020-04-11T11:00:00Z","year":2020,"_id":"32275081","source":"PubMed","week":"202015|Apr 06 - Apr 12","doi":"10.1002/jmv.25865","keywords":["sars-cov-2","infectivity","neutralization","pseudoviral particles"],"topics":["Diagnosis"],"weight":1,"_version_":1666138491689369601,"score":165.59384}]}